Attend ASIPP's 2014 Annual Meeting! Protect Your Practice AND Survive into the Future

 

| BROCHURE | ONLINE REGISTRATION | HOTEL | WEBSITE

 

 

Join us for exciting, informative, and in-depth breakout sessions of multiple areas of ipm, including
practice management, fromindustry leading presenters.

 

In an effort to meet the needs of interventional pain physicians and other providers as well, we have created Breakout Sessions with educational programs of the highest caliber covering topics of critical interest to interventional pain physicians, mid-level providers, and staff.

BREAKOUT SESSIONS

Controversies of Epidural Injections

Friday, April 4, 2014

• Are Transforaminal Epidurals Superior? Comparison of Caudal, Interlaminar, and Transforaminal
• Epidural Injections: Stenosis, Discogenic, Post-Surgery
• Cervical Epidural Injections: Interlaminar vs. Transforaminal
• Complications of Transforaminal Epidural Injections: Cervical Thoracic, and Lumbosacral
• Mechanism of Injury with Epidural Injections: Artery, Needle, Steroid, or Physician?
• Alternate Approaches Transforaminal: Safe Triangle, Post Ganglion, Retrodiscal, or Kambin Triangle

Emerging Concepts in IPM

Friday, April 4, 2014

• Ultrasound Basics
• Controversies of RFTN: Needle Placement, Connection, Pulsed, Cooled, and Lesion Size
• Diagnostic Facet Joint Nerve Blocks - 0%, 50%, 80%
• PRP and other Biological
• Therapeutic Facet Joint Nerve Blocks vs. Radiofrequency Neurotomy
• Managing Thoracic Outlet Syndrome
• Stem Cell Therapy

Practice Development

Friday, April 4, 2014.

• Practice Management: Scheduling, Billing, and Collections
• Developing and Managing a Value-Based Practice
• Trends in Marketing Your Pain Management Practice

Legal and Ethical Considerations

Friday, April 4, 2014

• Legal Considerations: Stark, Anti-Kickback, and Safe Harbors
• Evolving CMS Mandates with Reimbursement and Quality Reporting
• Ethical, Legal Considerations, and Regulation Requirements in Urine Drug Testing
• Key Steps in Managed Care Contracting
• Exhibitor Reception in Exhibit Hall

Emerging Evidence for Established Techniques

Saturday, April 5, 2014

• Percutaneous Adhesiolysis
• Discography: Provocation vs. Analgesia
• Spinal Cord Stimulation
• Intrathecal Implantables
• Sacroiliac joint Interventions
• Do We Need Steroids in Epidural Injections?
• Vertebroplasty vs. Kyphoplasty

Emerging Aspects of IPM

Saturday, April 5, 2014

• Cancer: Through Pain May Come a Cure
• Hydrodiscectomy
• Hip and Knee Injections for Interventionalists
• Genetic Testing: Fact vs. Fiction
• Abstract Presentations

Practice Management: Fraud and Abuse-Sleeping with the Enemy

Saturday, April 5, 2014

Here are the session topics:

• What Are We Facing in IPM? Fraud, Abuse, and RAC s
• Compliance for Success: OIG and HIPAA

Documentation Debacle

Saturday, April 5, 2014

Here are the session topics:

• Understanding Documentation Basics and Requirements: CPT, ICD-9, or ICD-10
• Documentation for Evaluation and Management Services
• Documentation for IPM Techniques and Other Services
• Interfacing Documentation with Coding

Doctor Payments on the Decline

Pharmaceutical company payments to health care professionals dropped between 2011 and 2012 among most of the companies and categories ProPublica tracks, driven in part by increased transparency as well as blockbuster drugs losing patent protection. Research payments, however, have increased among that group.

ProPublica

FDA Approves Headband Device for Migraine

 A headband delivering electrical nerve stimulation can prevent onset of migraine headaches and can be marketed for that purpose in the U.S., the FDA said Tuesday.

Called Cefaly, the Belgian-made device is the first to win FDA approval for migraine prevention and is also the first transcutaneous electrical nerve stimulation (TENS) system OK'd for any type of pain prevention, as opposed to acute treatment, the agency said.

The device is battery-powered and worn around the head, with the actual TENS stimulator centered on the forehead just above the eyes. It delivers a small, steady current to trigeminal nerve branches. Patients will be instructed to use the device once daily for a maximum of 20 minutes. It is approved for adults only.

MedPage Today

Docs Unprepared for Payment Reform

A pair of recent reports call into question the ability of physician practices to embrace health reform efforts.

Practices aren't staffed to become patient-centered medical homes (PCMHs), and little is known about how to best operate in a setting that rewards physicians for performance, the studies released in the last week found.

Only about half (53%) of more than 500 primary care practices reported having nurse practitioners or physician assistants, and a quarter (24%) had care managers or coordinators, Deborah Peikes, PhD, of Mathematica Policy Research in Princeton, N.J., and colleagues wrote in the Annals of Family Medicine. A mere 7% reported having pharmacists, social workers, community service coordinators, health educators, or nutritionists.

MedPage Today

U.S. Cocaine Consumption Declines by Half, While Marijuana Use Jumps

The use of cocaine dropped sharply across the United States from 2006 to 2010, while the amount of marijuana consumed increased significantly during the same period, according to a new report.

Studying illegal drug use nationally from 2000 to 2010, researchers found the amount of marijuana consumed by Americans increased by more than 30 percent from 2006 to 2010, while cocaine consumption fell by about half. Meanwhile, heroin use was fairly stable throughout the decade.

Methamphetamine consumption dramatically increased during the first half of the decade and then declined, but researchers did not have enough information to make a credible estimate of the drug's use from 2008 to 2010.

Health Canal

FDA Opioid Rulings Slammed

FDA decisions about prescription opioid painkillers have been inconsistent, and the agency should make future decisions with greater transparency, according to drug safety researchers.

While all extended-release oxycodone products (OxyContin and generics) are required to have abuse-deterrent properties, that's not the case for long-acting oxymorphone (Opana and generics) or hydrocodone (Zohydro), according to Lewis Nelson, MD, of NYU School of Medicine, and colleagues.

MedPage Today

Impending debut of potent prescription painkiller Zohydro fuels debate over dangers

A powerful new prescription painkiller that's packed with hydrocodone and provides 12-hour pain relief will be available in pharmacies in the next couple of weeks.

Both the manufacturer of Zohydro and the federal Food and Drug Administration say that the drug, a synthetic opioid, is safe if used correctly and is a necessary alternative for patients who have built up a tolerance to other opioids or can't tolerate opioids mixed with other medicines.

But local addiction-treatment experts and families who have lost loved ones to opiate overdoses say the new drug will contribute to the deadly heroin and pain pill epidemic. For them, a new prescription opiate is the last thing needed on the shelves of drugstores.

Buffalo News

Teens Likely to Get Opioid Rx for Headaches

Nearly half of teens who visit a doctor complaining of headache pain walk away with a prescription for a narcotic painkiller, researchers found.

And teens who sought headache treatment at an emergency department were twice as likely to get an opioid for their headache as those who saw a doctor in a different setting.

Opioids were go-to drugs for teen headache even though evidence-based guidelines do not recommend them for first-line treatment.

MedPage Today

Number of Uninsured Buying Coverage Under Health Law Is Rising

The number of previously uninsured consumers buying coverage under the health law has risen sharply in recent weeks, according to new research, a nascent signal of progress in the law's goal of reducing the ranks of the uninsured.

The overall share of uninsured people gaining coverage remains low, but the trend suggests more people could gain coverage as the enrollment period approaches its final weeks. Most people must pick health plans by the end of March, when open enrollment ends.

About 27% of 395 consumers surveyed in mid-February who enrolled in health-law coverage were previously uninsured, according to consultancy McKinsey & Co. That is up from about 11% in a previous McKinsey survey covering consumers who had chosen coverage as of January.

Wall Street Journal

 Access to this article may be limited.

Reimbursement provisions in FY15 budget: $400 billion in cuts

The Obama Administration released its proposed federal budget for fiscal year 2015 this week. Virtually all types of healthcare providers, health plans, and drug manufacturers would be impacted by the budget provisions if adopted as proposed - an unlikely scenario given the Republican House leadership's reaction to the document.

Hospitals will not be altogether pleased with many of the budget proposals. "Today's budget proposal includes some problematic policies that would undermine the ability of hospitals to improve the healthcare system and, ultimately, puts access to services at risk for the patients and communities we serve," said AHA President and CEO Rich Umbdenstock, in a statement.

Healthcare Finance News

Obama Gives Health Plans Added Two-Year Reprieve

The Obama administration further postponed a provision of the Affordable Care Act on Wednesday, the latest in a series of changes that have delayed or pared back the health overhaul so much that many of its ambitious goals won't be achieved during its first years in full effect.

Democrats sought to create a new health-care landscape when they passed the law in 2010, with millions of uninsured Americans gaining coverage, employers facing fines if they didn't insure workers and skimpy health plans disappearing.

But a series of delays by the administration-and decisions by states on implementing the law-have taken a toll. The latest delay came Wednesday, when federal officials said insurance companies could continue selling plans that don't meet the law's more rigorous standards until 2016 in some instances. It was the second time the administration delayed that requirement after the law's tougher standards prompted insurers to cancel millions of people's health plans last year. The latest delay averts another raft of cancellations before this year's midterm elections.

Wall Street Journal

Access to this article may be limited.

Opposition to Medicare Part D Changes Grows

Medicare's prescription drug program was controversial when it arrived, but a decade later it is widely considered to be a Washington success story. Now, though, the Obama administration is proposing a series of significant changes to fix what critics say isn't broken.

Administration officials say they want to help beneficiaries make good choices and save taxpayers money. But some patient groups, pharmaceutical manufacturers, and lawmakers in both parties are pushing back against various elements.

The regulation would affect several aspects of the Medicare drug program, also known as Part D, ranging from new limits on the number of plans insurers could offer consumers to new rules about what drugs those plans must cover. It also would prohibit exclusion of pharmacies from a plan's "preferred pharmacy network" as long as they agree to the plan's terms and conditions.

MedPage Today